Category: Uncategorized

OH PLEASE! THE URBAN MYTH OF THE COSTS TO DEVELOP A NEW DRUG perpetuates itself dishonestly. It only costs 1 Bn in bloated inefficient Big Pharma with huge carrying costs. But even this number is padded. Do they pay these sums for in-licensed drugs? Rarely. Usually these licenses are hundreds of millions, which pays back the investors in the licensee company very handsomely. You cannot talk out of both sides of the mouth and retain credibility, except with gullible reporters! Let's keep the dialogue honest!! View in LinkedIn

BUST THE URBAN MYTH THAT ALL DRUG DEVELOPMENT COSTS OVER 1Bn USD. These articles continue, sadly. The VC specialty pharma investments, hundreds, would mot exist if this were true. Again: Big Pharma costs for developing a new drug are staggering because of staggering inneficiencies, which do not exist in small companies. View in LinkedIn

A FRESH LOOK AT DATA SUGGESTS BIO RETURNS ARE EARLIER THAN THOUGHT. This shows that some strongly held VC views are prejudices without a factual basis. Great work collecting the data! Make this break the urban myth! http://lnkd.in/wVEBEz View in LinkedIn

NANO TNF ALPHA FOR CANCER ENTERS PHASE II. BETTER TARGETING, LESS TOXICITY. View in LinkedIn

NANOPARTICLE PAYLOAD MODELING. View in LinkedIn

MUTATION TARGETS IN TUMORS ARE IMPORTANT. View in LinkedIn

SMART INSULIN NANOPARTICLES RELEASE DRUG IN RESPONSE TO GLUCOSE AND LASTS FOR TEN DAYS. Now we are trucking! View in LinkedIn

MONOCLONAL THERAPIES FOR CANCER CONTINUE TO DOMINATE THE LANDSCAPE. The wave of approvals of MAb treatments for cancer continues unabated. However, does adding a few months to those ghastly survival graphs constitute forward motion in the majority of cases? The personalized medicine approach offers a rational solution by matching the treatment to the tumor's biology. These individual mutations confer drug resistance or susceptibility, and are becoming the focus of new drug therapies. http://m.seekingalpha.com/article/1403251-bristol-myers-has-the-future-of-oncology-therapies?source=yahoo View in LinkedIn

JAPAN AND CATALUNYA SHARE IMPORTANT SIMILARITIES. Both have invested in the Knowledge Revolution. Both have created decent Bioclusters. Both need a real success to be a Tipping Point for capital access in Biopharma. Both have the Nail That Sticks Up issue (ambition is too individualistic). Both need access to experienced international entrepreneurs. Both are very honest cultures which place a high value on friends and family. There are lessons to be learned from each for the other. View in LinkedIn

THE LIFE SCIENCE IPO WINDOW IS FINALLY OPENING after five years of closure. Liquidity is a key driver of VC investments which also dried up in this period. This is a very hopeful sign. http://lnkd.in/Dund3M View in LinkedIn